Loading
Becton Dickinson & Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Aug 2025.
Becton Dickinson & Co: what insiders have been doing
Becton Dickinson & Co, classified in the Healthcare & Pharma sector, is a listed company based in San Jose, United States, founded in 1897. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 70 filings signed by 31 insiders.
There is no open-market purchase to report; the filings show 20 sales worth €1.8M by 5 insiders. The amount is not disclosed for 3 filings. One trade stands out by size: a sale of €666k from Polen Thomas E Jr, disclosed on 14 August 2026, or 0.0015% of market capitalisation.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 70 filings here. Looking back to 2016, when coverage begins, insiders filed 2 purchases and 65 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 September 2025), the company reported revenue of 21.84 bn USD and net income of 1.68 bn USD, with a dividend of 4.16 USD per share.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
322
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€11M
65 ops. · all time
Who traded when
BuySaleMichael Feld14 sales
Michael David Garrison8 sales
Roland Goette3 sales
Scott Bertram l3 sales
Shan David3 sales
Byrd Richard2 sales
+5 other insiders
Since the insiders bought
- -6.1%Entry 166.70 · Close at T+365 156.50
- -8.5%Entry 162.81 · Close at T+365 149.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 29 September 2026
Declarations322 total
76 shares@ US$183.700.0000% mcap7.9% of flowCommon StockSEC:0001628280-26-063882:0
76 shares@ US$183.820.0000% mcap54.4% of flowCommonSEC144:0001950047-26-009847
190 shares0Common StockSEC:0001628280-26-060580:0
165 shares@ US$188.490.0001% mcap18.6% of flowCommon StockSEC:0001628280-26-059269:0
165 shares@ US$189.780.0001% mcap72.9% of flowCommonSEC144:0001950047-26-008719
1,049 shares0Common StockSEC:0001628280-26-058647:0
1,330 shares@ US$187.9650.0005% mcap100.0% of flowCommonSEC144:0001950047-26-008451
43,278 shares@ US$167.250.014% mcap29.9% of flowCommon StockSEC:0001628280-26-057166:0
39,126 shares@ US$185.000.014% mcap29.9% of flowCommon StockSEC:0001628280-26-057166:1
4,152 shares@ US$185.000.0015% mcap3.2% of flowCommon StockSEC:0001628280-26-057166:2
4,152 shares@ US$183.580.0015% mcap100.0% of flowCommonSEC144:0001950047-26-008086
2,438 shares@ US$180.840.0009% mcap4.8% of flowCommon StockSEC:0001628280-26-056366:0
2,438 shares@ US$180.83570.0009% mcap100.0% of flowCommonSEC144:0001628280-26-055581
1,500 shares@ US$165.620.0005% mcap100.0% of flowCommonSEC144:0001950047-26-007503
75 shares@ US$157.130.0000% mcap7.2% of flowCommon StockSEC:0001628280-26-049989:0
75 shares@ US$156.360.0000% mcap100.0% of flowCommonSEC144:0001950047-26-007318
1,935 shares0Common StockSEC:0001628280-26-047193:1
14,342 shares0Common StockSEC:0001628280-26-047193:0
75 shares@ US$151.3827.1% of flowCommonSEC144:0001950047-26-006547
75 sharesCommon StockSEC:0001628280-26-045864:0
1,100 sharesCommon StockSEC:0001628280-26-045374:0
1,100 shares@ US$143.92100.0% of flowCommonSEC144:0001950047-26-006468
1,100 sharesCommon StockSEC:0001628280-26-042571:0
1,100 shares@ US$152.04100.0% of flowCommonSEC144:0001950047-26-005893
2,764 shares@ US$146.350.0009% mcap1.7% of flowCommon StockSEC:0001628280-26-040095:2
25 of 322 declarations
About Becton Dickinson & Co
Becton, Dickinson and Company (BDX) is a major U.S. healthcare company listed on the NYSE in the United States. For French-, Belgian- and Swiss-based investors, BD is best viewed as a global medical technology platform with a broad industrial footprint, recurring consumables exposure, and deep relationships across hospitals, laboratories, and pharmaceutical manufacturers. The company was founded in 1897 by Maxwell Becton and Fairleigh Dickinson and is headquartered in Franklin Lakes, New Jersey. Over time, BD has evolved from a classic medical supplies manufacturer into a diversified med-tech group with strong positions in medication delivery, diagnostics, biosciences, and interventional care.
BD’s business model has historically been organized around three worldwide segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical includes medication delivery systems, medication management solutions, and pharmaceutical systems. BD Life Sciences covers biosciences and diagnostic solutions, including tools used in research, clinical testing, and laboratory workflows. BD Interventional spans surgery, urology, and critical care-related products used in procedural and acute-care settings. This mix gives BD a combination of installed-base revenue, consumables, and technology-driven recurring demand that is often attractive in a defensive healthcare portfolio.
Read moreShow less
Competitive positioning is anchored in scale, brand recognition, manufacturing capability, and switching costs in clinical settings. BD is widely recognized as a core supplier to hospitals and laboratories, with products that include syringes, needles, IV and infusion-related devices, specimen management tools, diagnostic platforms, and a range of interventional and surgical products. The company also has a meaningful presence in pharmaceutical delivery, where its technologies help enable drug-device combination products and biologic delivery systems. That pharma-facing exposure has become increasingly strategic as biologics, GLP-1 therapies, and specialty injectables continue to grow.
Geographically, BD operates on a global basis, with significant sales and operations outside the United States, including Europe and Asia. At the same time, it maintains a large U.S. manufacturing base and has recently highlighted additional domestic investments to support supply-chain resilience and capacity expansion. This matters for investors because BD combines multinational revenue diversification with a strategically important U.S. industrial footprint.
Recent developments have been important. In 2025, BD announced several product and platform milestones, including advances in wearable injector technology, pharmacy automation, and hospital interoperability solutions. The company also announced a definitive agreement to combine its Biosciences & Diagnostic Solutions business with Waters Corporation, a major portfolio step that signals a sharper focus on core medical and interventional franchises. In 2026, BD disclosed a $110 million investment to expand prefillable syringe production in the United States, supporting biologic and GLP-1 drug delivery and broader pharmaceutical reshoring. Overall, BD remains a high-quality, relatively defensive healthcare name on the NYSE, with a long operating history, strong market standing, and an active capital-allocation and portfolio-shaping agenda.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
